Notice: Undefined index: HTTP_REFERER in /home/genmedic/public_html/wp-content/plugins/easy-upload-files-during-checkout/inc/functions.php on line 303
Buy MyDacla 60 mg | Genmedicare.com - My Generic Store
Notice: WC_Cart::get_cart_url is deprecated since version 2.5! Use wc_get_cart_url instead. in /home/genmedic/public_html/wp-includes/functions.php on line 3853

Notice: WC_Cart::get_checkout_url is deprecated since version 2.5! Use wc_get_checkout_url instead. in /home/genmedic/public_html/wp-includes/functions.php on line 3853
Menu

MyDacla 60 mg

Buy MyDacla 60 mg (Daclatasvir) Online, Daclatasvir is one of the new direct-acting antiviral drugs that target different steps of the hepatitis C virus (HCV) lifecycle.MyDacla is used to treat genotype 1 and genotype 3 chronic hepatitis C in adults with or without cirrhosis.MyDacla is given together with another drug called Sovaldi (sofosbuvir).

SKU: 485.
Category:

$165.00$460.00

Compare

Available Options:

Description

MyDacla 60 mg (Daclatasvir)

What is MyDacla?

MyDacla (Daclatasvir) is an antiviral medicine that prevents hepatitis C virus (HCV) from multiplying in your body. MyDacla is used to treat genotype 1 and genotype 3 chronic hepatitis C in adults with or without cirrhosis. MyDacla is given together with another drug called Sovaldi (sofosbuvir).

How does MyDacla work?

Daclatasvir prevents RNA replication and virion assembly by binding to NS5A, a nonstructural phosphoprotein encoded by HCV. Binding to the N-terminus of the D1 domain of NS5A prevents its interaction with host cell proteins and membranes required for virion replication complex assembly.

Daclatasvir must be used in combination with other medicines that attack the hepatitis C virus in different ways. If daclatasvir is used on its own there is a high chance that the hepatitis C virus will become resistant to it.

What is MyDacla used for?

MyDacla (Daclatasvir) is used to treat chronic hepatitis C infections (genotype 1, 3 and 4) in adults with uncomplicated liver disease whose liver is still functioning correctly (compensated liver disease). MyDacla may be used in people who have not yet received treatment for their hepatitis C, or for people whose disease has not improved with previous treatment. MyDacla may be used in combination with sofosbuvir (Sovaldi), either with or without ribavirin (Rebetol), or with ribavirin plus peginterferon alfa (ViraferonPeg or Pegasys).

Important information

Serious drug interactions can occur when certain medicines are used together with daclatasvir. Tell each of your healthcare providers about all medicines you use now, and any medicine you start or stop using.

Before taking this medicine

You should not use MyDacla if you are allergic to daclatasvir. If you take daclatasvir with sofosbuvir, there may be other reasons you should not take this combination treatment. Tell your doctor about all your medical conditions.

Some medicines can interact with MyDacla and should not be used at the same time. Your doctor may need to change your treatment plan if you use any of the following drugs: rifampin, carbamazepine, phenytoin.

To make sure MyDacla is safe for you, tell your doctor if you have:

  • liver problems other than hepatitis C;
  • heart disease;
  • if you also use amiodarone (a heart rhythm medicine); or
  • if you have received a liver transplant.

It is not known whether MyDacla will harm an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant.

It is not known whether daclatasvir passes into breast milk or if it could harm a nursing baby. Tell your doctor if you are breast-feeding a baby.

MyDacla is not approved for use by anyone younger than 18 years old

How is MyDacla taken?

Daclatasvir is available in 30 and 60mg tablets, and the usual dose is 60mg once daily with or without food. It must be used in combination with other hepatitis C medications and is not effective if taken alone. Treatment should be managed by a doctor who has experience treating hepatitis C. People with HCV genotypes 1 or 4 who are being treated for the first time and do not have liver cirrhosis should take daclatasvir plus sofosbuvir for 12 weeks. Due to limited clinical trial data, there is still uncertainty about the best way to treat people with genotypes 2, 3 or 4.

What happens if I miss a dose?

Take the missed dose as soon as you remember. Skip the missed dose if it is almost time for your next scheduled dose. Do not take extra medicine to make up the missed dose.

What happens if I overdose?

Seek emergency medical attention or call to your doctor.

What should I avoid while taking MyDacla?

Taking MyDacla will not prevent you from passing hepatitis C to other people. Do not have unprotected s** or share razors or toothbrushes. Talk with your doctor about safe ways to prevent HCV transmission during s**. Sharing drug or medicine needles is never safe, even for a healthy person.

MyDacla side effects

Get emergency medical help if you have signs of an allergic reaction to MyDacla: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

FAQ

Q: What is the Generic Name for the trade name drug “Daklinza” ?

A: Daclatasvir mepesuccinate is Generic Name for the trade name drug MyDacla.

Q: What is the Manufacturer Name of MyDacla ?

A: MyDacla is manufactured by Natco Pharma, India

Q: Is MyDacla approved by FDA?

A: Yes, MyDacla is approved by FDA.

Q: What is the dosage and form of MyDacla is available?

A: MyDacla is available 30 mg & 60 mg film-coated tablets

Sourcing:

GenMedicare is able to source MyDacla Brentuximab Vedotin (Cancer Treatment Medicines) from across the globe, and has ability to supply. Indian Pharma offers its customers worldwide access to the best available treatment.

Delivery:

GenMedicare is able to dispense any valid prescription in shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to Patients address only from India.

Is MyDacla available in India?

MyDacla is a pharmaceutical drug that legally requires a medical prescription to be dispensed.

GenMedicare facilitates Export of cancer medicines on the named patient supply. GenMedicare is facilitator providing input

  • On availability in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore and Pune etc.)
  • Medicine Price.
  • Finding Genuine and reliable source from Europe, USA and Australia
  • Ensuring 100% transparency.

MyDacla can be made available Europe, USA and Australia, GenMedicare can facilitate the supply of MyDacla(prescription medicines) to all locations in the world and in India after fulfilling the legal requirement (if applicable)

Please email us for bulk discount, We take guarantee of quality and delivery anywhere in the world as per the buyer’s requirements.

How order will be confirmed ?

The order will be confirmed only after the receipt of

  • Valid prescription of Oncologist
  • Import permit if applicable
MyDacla From us.

Before contacting us please take into account that the medicine has to be prescribed by a doctor, and you must provide the prescription to us and we will verify it with your doctor.

We are able to deliver the MyDacla to almost every country in the world, directly to your doctor’s office or through a net of allied pharmacies. If you want more information about MyDacla , to get more information about the HCV visit our Hep C Blog To get your best MyDacla quote visit our online pharmacy. Generic components: Daclatasvir Usually prescribed to treat chronic hep c infection Original Brand Manufactured by Bristol-Myers Squibb 
MyDacla Launch

On 17th December 2105 Natco Pharma got approval for generic Daclatasvir Dihydrochloride (“Daclatasvir”) tablets, MyDacla 30mg & MyDacla 60mg, from Drugs Controller General (India). Daclatasvir (MyDacla) is the first-in-class NS5A inhibitor used in combination with Sofosbuvir for the treatment of patients with chronic hepatitis C virus (HCV) genotype 3 infection. Compared to other treatment options, this combination not only increases the cure rate, but is also regarded as a valuable treatment option in some of the difficult-to-treat HCV patient subsets.

U.S. Food and Drug Administration approved MyDacla (Daclatasvir) for use with sofosbuvir to treat hepatitis C virus (HCV) genotype 3 infections on July 24, 2015 . MyDacla (Daclatasvir) is the first drug that has demonstrated safety and efficacy to treat genotype 3 HCV infections without the need for co-administration of interferon or ribavirin, two FDA-approved drugs also used to treat HCV infection.

Additional information

Equivalent Brand

Daklinza

Strength

60 mg

Generic Name

Daclatasvir

Manufacturer

Mylan Pharma, India

Pharmaceutical Form

Tablet/s

Reviews

There are no reviews yet.

Be the first to review “MyDacla 60 mg”